Aspire Biopharma Holdings, Inc.
Filed Sep 18, 2025.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Sep 18, 2025
ASBP$8.09+19.7%Stored close · as of Nov 6, 2026
Contents
SELECTED DEFINITIONS
When used in this prospectus, unless the context otherwise requires:
| ● | “Board” refers to the board of directors of Aspire; |
|---|---|
| ● | “Bylaws” refers to the existing bylaws of Aspire currently in effect; |
| ● | “Charter” refers to the existing amended and restated certificate of incorporation of Aspire currently in effect; |
| ● | “common stock” refers to shares of common stock of Aspire, par value $0.0001 per share; |
| ● | “Closing” refers to the closing of the Merger; |
| ● | “Aspire” refers to Aspire Biopharma Holdings, Inc., a Delaware corporation; |
| ● | “DGCL” refers to the General Corporation Law of the State of Delaware; |
| ● | “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; |
| ● | “GAAP” refers to accounting principles generally accepted in the United States of America; |
| ● | “JOBS Act” refers to the Jumpstart Our Business Startups Act of 2012; |
| ● | “Nasdaq” refers to the Nasdaq Global Market; |
| ● | “preferred stock” refers to shares of “blank check” preferred stock, each having a par value of $0.0001; |
| ● | “Stockholders” refers to the stockholders of Aspire; |
| ● | “pro forma” refers to giving pro forma effect to the Merger; |
| ● | “Sarbanes-Oxley Act” refers to the Sarbanes-Oxley Act of 2002; |
| ● | “SEC” refers to the United States Securities and Exchange Commission; |
| ● | “Securities Act” refers to the Securities Act of 1933, as amended; |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.